April 22 (Reuters) - Abeona Therapeutics said on Monday the U.S. health regulator had declined to approve its treatment for a rare skin blistering condition. (Reporting by Pratik Jain in Bengaluru; Editing by Sriraj Kalluvila)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.5 USD | +5.39% | -0.88% | -10.58% |
May. 30 | Stifel Starts Abeona Therapeutics With Buy Rating, $21 Price Target | MT |
May. 16 | Cantor Fitzgerald Adjusts Price Target on Abeona Therapeutics to $21 From $36, Maintains Overweight Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.57% | 176M | |
+45.72% | 57.87B | |
+40.71% | 40.25B | |
-6.70% | 39.94B | |
-5.16% | 28.54B | |
+11.41% | 26.4B | |
-20.25% | 19.33B | |
+29.66% | 12.4B | |
-0.98% | 12.23B | |
+23.78% | 12.2B |
- Stock Market
- Equities
- ABEO Stock
- News Abeona Therapeutics Inc.
- US FDA declines to approve Abeona's skin disorder treatment